Document Detail


Magnetic targeting of human peripheral blood CD133+ cells for skeletal muscle regeneration.
MedLine Citation:
PMID:  23298291     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Skeletal muscle injuries often leave lasting functional damage or pain. Muscle injuries are routinely treated conservatively, but the most effective treatment to promote the repair of injured muscles has not yet been established. Our previous report demonstrated that human peripheral blood-derived CD133(+) cell transplantation to rat skeletal muscle injury models inhibited fibrosis and enhanced myogenesis after injury. However, the acquisition of a sufficient number of cells remains the limitation for clinical application, as the CD133(+) population is rare in human blood. In this study, we applied a magnetic cell targeting system to accumulate transplanted cells in the muscle injury site and to enhance the regenerative effects of CD133(+) cell transplantation, focusing on the fact that CD133(+) cells are labeled with a magnetic bead for isolation. For the magnetic cell targeting, the magnet field generator was set up to adjust the peak of the magnetic gradient to the injury site of the tibialis anterior muscle, and 1×10(4) human peripheral blood CD133(+) cells were locally injected into the injury site. This cell number is 10% of that used in the previous study. In another group, the same number of CD133(+) cells was injected without magnetic force. The CD133(+) cells transplanted with the magnetic force were more accumulated in the muscle injury site compared with the CD133(+) cells transplanted without the magnetic force. In addition, the transplantation of CD133(+) cells under the magnetic control inhibited fibrous scar formation and promoted angiogenesis and myogenesis, and also upregulated the mRNA expression of myogenic transcription factors, including Pax7, MyoD1 and Myogenin. However, the transplantation of CD133(+) cells without the magnetic force failed to demonstrate these effects. Thus, our magnetic cell targeting system enables transplantation of a limited number of CD133(+) cells to promote the repair of skeletal muscle injury.
Authors:
Shingo Ohkawa; Naosuke Kamei; Goki Kamei; Ming Shi; Nobuo Adachi; Masataka Deie; Mitsuo Ochi
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2013-02-25
Journal Detail:
Title:  Tissue engineering. Part C, Methods     Volume:  19     ISSN:  1937-3392     ISO Abbreviation:  Tissue Eng Part C Methods     Publication Date:  2013 Aug 
Date Detail:
Created Date:  2013-06-21     Completed Date:  2014-01-17     Revised Date:  2014-08-05    
Medline Journal Info:
Nlm Unique ID:  101466663     Medline TA:  Tissue Eng Part C Methods     Country:  United States    
Other Details:
Languages:  eng     Pagination:  631-41     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antigens, CD*
Female
Glycoproteins*
Heterografts
Humans
Magnetic Fields*
Male
Muscle Development
Muscle, Skeletal / injuries*,  metabolism*,  pathology
Peptides*
Rats
Rats, Nude
Regeneration*
Stem Cell Transplantation*
Stem Cells / metabolism*
Chemical
Reg. No./Substance:
0/AC133 antigen; 0/Antigens, CD; 0/Glycoproteins; 0/Peptides
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Dietary grape polyphenol resveratrol increases mammary tumor growth and metastasis in immunocompromi...
Next Document:  A design of experiments to optimize a new manufacturing process for high activity protein-containing...